Deal snapshot: Royalty Pharma Acquires Partial Royalty Interest on Prevymis.

MANews-(C)2009-2020

US-based pharmaceutical royalties acquirer Royalty Pharma and AiCuris Anti-infective Cures GmbH, a company in the discovery and development of drugs against infectious diseases, have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis (letermovir) from AiCuris for a one-time payment of USD 220m, the companies said.

Prevymis is licensed by MSD, the tradename of Merck and Co. Inc. (NYSE: MRK), Kenilworth, NJ, USA. The product was approved by the US Food and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT